0001193125-11-350968.txt : 20111223 0001193125-11-350968.hdr.sgml : 20111223 20111222173123 ACCESSION NUMBER: 0001193125-11-350968 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111222 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20111223 DATE AS OF CHANGE: 20111222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 111278426 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 d274817d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: December 22, 2011

 

(Date of earliest event reported)

ABIOMED, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   04-2743260
(State or other Jurisdiction of Incorporation)   (IRS Employer Identification Number)

0-20584

(Commission File Number)

22 Cherry Hill Drive

Danvers, MA 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 7.01 Regulation FD Disclosure.

Today, Abiomed participated in an investor call hosted by Wunderlich Securities, Inc. to discuss the status of obtaining Impella specific Current Procedural Terminology (CPT) codes for purposes of physician payment, publications of the Intra Aortic Balloon (IAB) device and other matters.

On the call, Abiomed confirmed that it had sought specific CPT codes for its Impella 2.5 and that The Society for Angiography and Interventions (SCAI) continues its support for Impella technology and is recommending specific CPT codes for Impella. In addition, Abiomed commented on the critical IAB device publications noted in the table below.

 

Publication

  

Study

  

Journal Year

  

N of Patients

  

Benefit of IABP

Sjauw et al.

   Meta-analysis   Eur Heart J 2009   11,538   No

Redwood et al.

   Randomized   JAMA 2010   301   No

Patel et al.

   Randomized   JAMA 2010   337   No

Curtis et al.

   NCDR Registry   Circulation CQO 2011   18,990   No
     

 

  

Total # of patients

     31,166  

Abiomed also confirmed that it has not changed its previously announced annual revenue guidance of $120M to $125M.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

ABIOMED, INC.
By:   /s/ Robert L. Bowen
 

Robert L. Bowen

Chief Financial Officer

Date: December 22, 2011